1. Introduction 2. Genotypes of HBV 2-1. Clinical differences of HBV genotypes 2-1-1. Clinical differences between HBV genotypes A and D 2-1-2. Clinical differences between HBV genotypes B and C 2-2. Responses of HBV genotypes to antiviral therapy 2-2-1. IFN-a 2-2-2. Nucleoside and nucleotide analogues SUMMARY: Hepatitis B virus (HBV) has been classified into 10 genotypes (A-J) according to genome sequence divergence. HBV genotypes have a distinct geographical distribution. As chronic HBV infection is endemic in the Asian region, genotypes B and C prevail there, and genotypes A and D are mainly found in the western world and Europe. Genotypes A, B, C, and D have been studied most extensively. In Europe and Asia, most patients with genotypes A and B have acute hepatitis B; however, some mutants may tend to cause fulminant hepatitis B. Many studies have indicated that the severity and outcomes of chronic hepatitis B infections are more serious in patients with genotypes C and D than in those with genotypes A and B. Cirrhosis and hepatocellular carcinoma (HCC) are more frequently diagnosed in carriers of genotypes C and D than in those of genotypes A and B. Accumulating evidence indicated that higher plasma HBV DNA levels, infection with HBV genotype C, as well as mutations at 1653T, 1753V, and A1762T/G1764A are independently associated with the risk of HCC in Asian men. However, the therapeutic responses differ with regard to the different HBV genotypes. For example, the response to interferon-a treatment in patients with genotypes A and B was better than that in patients with genotypes C, D, and mixed genotypes. Some studies have shown seroconversion after treatment, i.e., genotypes A and C may switch to genotypes D and B, respectively. Some reports indicated a correlation between the emergence of the hepatitis B e antigen-negative variant in patients with genotypes C and D and worsening of liver injury without sustained response. In order to provide better treatment options for these poorly responding patients, further studies, e.g, novel immunomodulatory therapies, are required. Many studies have shown that HBV genotypes have remarkable clinical and epidemical differences; however, HBV sub-genotypes, mixed genotype infections, and the effect of different genotypes on the treatment of HBV infections require further studies.
Introduction
Worldwide, it is estimated that more than 4 billion people have been infected with hepatitis B virus (HBV) (1), and 350 million individuals have been diagnosed with chronic HBV infection (2) . HBV infection has a wide spectrum of liver diseases, ranging from acute or fulminant hepatitis (FH), chronic hepatitis, and cirrhosis to hepatocellular carcinoma (HCC). The annual mortality associated with persistent HBV infection is approximately 1.2 million (3). Despite the availability of safe and effective vaccines for more than two decades, HBV infection is still regarded as a global health problem. Asia is a hyperendemic area for HBV infection; the primary infection occurs mainly during early childhood and through perinatal transmission, the major genotypes are B and C, which leads to a very high chronic rate. However, in North America and Northern Europe, the prevalence of HBV is lower, sexual and intravenous drug use are the major modes of transmission, and the major genotypes are A and D (4, 5) . Thus, in order to control the spread of HBV and to prevent progression to end-stage liver diseases and HCC, proper treatment of patients with chronic HBV infection is needed. There are differences in the hepatitis B genotype that are associated with virus replication, virus variation, disease prognosis, and the efficacy of antiviral therapy. Thus, heterogeneity in the global distribution of HBV genotypes may account for differences in the clinical outcomes of patients with HBV infection and different responses to antiviral treatment. In this paper, the correlation between HBV genotypes and clinical outcomes is reviewed. HBV subgroups have been identified within different HBV genotypes when an intra-genotype difference of À4z and º 8z was applied to the complete nucleotide sequence. This approach resulted in subgroups A1-A7 of HBV genotype A, B1-B9 of HBV genotype B, C1-C16 of HBV genotype C, D1-D8 of HBV genotype D, and F1-F4 of HBV genotype F, with distinct geographical distributions (18) (19) (20) (21) (22) .
2-1. Clinical differences of HBV genotypes
The clinical course of infection with the HBV virus depends on the patient's age, immune response, and the virus strain with which the individual has been infected. Several studies have revealed an association of HBV genotypes with different clinical outcomes of liver diseases.
2-1-1. Clinical differences between HBV genotypes A and D In Europe, most patients with genotype D are reported to have acute hepatitis B, while most patients with genotype A have chronic hepatitis B (23). Earlier, acute HBV infections in Europe were found to be associated with genotype D, but recently, it has been demonstrated that genotype A is the most prevalent one amongst patients with acute hepatitis B. Similarly, a study from Japan demonstrated that the HBV genotype A is the most prevalent one in patients with acute hepatitis B, whereas it is genotype C in patients with chronic HBV infection. There have been few reports on genotype correlations in patients with FH (24) . Genotype D may lead to a more severe disease, because HBV mutants have been found leading to FH.The majority of patients with FH were found to have an A 1896 precore stop codon mutation. Yuasa et al. (23) found that this mutation mostly belonged to genotype B, and fulminant genotype B strains differed from non-fulminant strains by a specific mutation in the X gene.
A significantly higher number of patients infected with genotype A or D were found to be anti-HBe-positive, and among the anti-HBe-positive patients, those infected with genotype D had significantly higher alanine transaminase (ALT) levels (25) .
During the carrier state, low hepatitis B e antigen (HBeAg) levels are marked by HBeAg negativity with anti-HBe positivity, low HBV DNA levels, and repeated normal ALT levels in Baig et al. (20) . The highest prevalence of genotype D was found in carriers of hepatitis B surface antigen (HBsAg) who were symptom-free and whose liver function tests were normal. These patients have an excellent prognosis and the risk of HCC was low over the mean follow-up, which was well supported by a long-term follow-up period of about 30 years. The prognosis of inactive carriers is, in general, good and well supported by long-term follow-up studies. An estimated 20z to 30z of HBsAg carriers may experience reactivation of hepatitis B with elevation of biochemical levels and high serum DNA levels with or without seroconversion to HBeAg. HBV reactivation is usually asymptomatic, but it may mimic active viral hepatitis (20, 26, 27) .
Chronically infected subjects have a 100 times increased risk of HCC compared to non-carriers. HBsAg positivity increases the risk of developing HCC by 10-fold and HBeAg positivity by 60-fold, whereas a detectable HBV DNA level yields a 4-fold increased risk of HCC. Regarding the genotype distribution, HBV genotype D was most prevalent among HCC patients and genotype A among cirrhosis patients (28) .
Genotype A that sustains biochemical and virological remission is not common in patients with genotype A, who had HBeAg seroconversion. These patients had also higher rates of HBsAg clearance. Gerner et al. observed that patients who were infected with HBV genotype A had a genotype switch from HBV genotype A to D after treatment with interferon (IFN) and relapse. Chen observed that the dominant genotype C changed to genotype Ba (B2) after anti-HBVeAg (anti-HBe) seroconversion. Originally, HBV B2 co-existed as a minor population with HBV genotype C during the early course of acute HBV infection, then emerged, and gradually became the dominant genotype.
The HBeAg-negative phenotype is much more prevalent in specific genotypes (D À A). Some reports indicate a correlation between the emergence of an HBeAgnegative variant and worsening of liver injury with a poor prognosis, while others suggest that the emergence of an HBeAg-negative variant correlates with less liver injury and viral clearance. No previous report has described persons who were initially infected with HBeAgnegative mutants that became predominant during and after seroconversion, suggesting immune selection as opposed to a replication advantage (29-31).
2-1-2. Clinical differences between HBV genotypes B and C HBV genotypes B and C were present in about 40z and 50z, respectively, of patients with an acute form of liver disease. In contrast, genotype C was found in 86z of patients with chronic liver disease and 68.4z of patients with acute exacerbation of chronic liver disease, suggesting that the distribution of the HBV genotype B in acute forms of liver disease was higher than that seen in chronic forms of the disease. Interestingly, the distribution of genotype B was higher in patients with FH than in patients with acute hepatitis; in addition, a stronger association of genotype B with more severe acute forms of liver disease was noted (23) . In Japan, genotypes B and C are predominant as compared to other Asian countries, but À90z of chronic carriers have genotype C. In the group of patients º30 years old, the majority of patients with chronic hepatitis B were positive for HBeAg and the rate of positivity for HBeAg was not significantly different between patients infected with genotypes B and C. HBeAg was not detected in the majority of patients infected with genotype B in the group of patients À30 years old. Most patients infected with genotype C were positive for HBeAg in the group À30 years old (24) .
Development of liver cirrhosis was commonly seen in patients with genotype B, and the majority of patients were HBeAg-negative at the initial diagnosis of chronic hepatitis. Most carriers, who were infected with genotype B and showed seroconversion from HBeAg to antiHBe, were º30 years old and became HBeAg-negative inactive carriers. The status of the HBeAg and anti-HBe antibody correlated with that of mutations in precore regions. Most patients infected with genotype B showed the precore mutation before the age of 30 years, absence of HBeAg production, followed by reduction in HBV-DNA levels (32) .
The majority (72.0z) of patients with genotype C who converted from being HBeAg-positive to HBeAgnegative after treatment with IFN had ALT abnormalities and were HBV DNA-positive, although HBeAg disappearance was associated with sustained remission of viral replication and liver disease. These findings suggest that HBeAg disappearance signifies a decrease in viral replication and liver damage in most patients with genotype B, but not in the majority of patients with genotype C. Higher frequency of HBeAg positivity, longer duration of the immune clearance phase, and more frequent core promoter mutations of HBV genotype C may contribute to the poor clinical outcomes of patients with genotype C compared to those of patients with genotype B infection (33) .
HBeAg-negative chronic hepatitis B is characterized by frequent exacerbation of hepatitis, which probably increases the risk of cirrhosis, hepatocellular failure, and HCC. In China, genotype C is the major genotype (accounting for 83.2z), which is similar to the HBV genotype distribution in China (34), where genotype B was more frequently found in patients with mild hepatic inflammation (asymptomatic carriers), while genotype C was more frequently noted in those with advanced liver disease. Many studies on the association between HBV genotype and the risk of HCC have been conducted in Asia (35) (36) (37) (38) .
In a study by Kao et al., a large number of Taiwanese HCC patients were examined and the results were compared with those of patients with cirrhosis and asymptomatic carriers. The authors found that genotype C was more common in cirrhotic patients (39) . In a prospective study where a large number of HBV cirrhotic patients were followed-up, genotype C-infected patients developed HCC more frequently than genotype B-infected patients (40) . A higher disease-inducing capacity of HBV genotype C compared to genotype B has been observed. For example, patients who were infected with genotype C and had HBV levels greater than 5.90 log 10 copies/mL had a 26.5-fold higher risk of HCC than patients who were infected with other HBV genotypes and HBV DNA levels lower than 4.32 log 10 copies/mL. The magnitude of this relative risk suggests that the HBV viral load and genotype may help to identify HBV carriers who are at high risk of disease progression to HCC (41) .
There was also a striking age-dependent difference in the genotypes of Taiwanese HCC patients. In HCC patients older than 50 years, genotype C was the most prevalent, but in patients younger than 50 years, genotype B was the most common. It was suggested that genotype C infection leads to HCC through cirrhosis (34) . This result may conflict with that of a Japanese study (36) , where genotype B-infected patients with HCC were older than HCC patients with genotype C. This discrepancy may be explained by the sub-genotype of genotype B, because HBV genotype B can be further classified into two distinct sub-genotypes, i.e., the Japanese subgroup Bj with no indication for recombination events and an Asian subgroup called Ba, which shows recombination of the precore and core region from HBV genotype C. Since HBeAg and the double mutation in the core promoter (A1762T/G1764A) are more frequently found in carriers of subtype Ba than Bj (42), the variation of Ba and Bj (B1) may explain the different prevalence of HCC in genotype B patients in Taiwan and Japan.
A recent study showed that HBV sub-genotypes Ba, C1 (Cs), and C2 (Ce) are the most prevalent HBV variants in China (43) . In this study, 211 patients were enrolled in the Guangdong province, including 132 patients with chronic HBV infection, 32 with liver cirrhosis, and 47 with HCC. HBV Ba was found in 51z (108/211), HBV C1 in 33.6z (71/211), and HBV C2 in 15.2z (32/211) of the patients. The distribution of the HBV genotype C was greater among patients in the liver cirrhosis and HCC groups than among patients in the chronic hepatitis group, while the distribution of HBV genotype B was greater among the chronic hepatitis patients than among the liver cirrhosis and HCC patients. HBV C1 had the strongest association with the A1762T/G1764A double mutation, HBV Ba had the lowest association with the A1762T/G1764A double mutation, and HBV C2 had intermediate frequencies of this mutations. The mutations at 1653T and 1753V were specifically associated with C2 and C1, respectively. Multivariate analyses showed that the 1653T, 1753V, and A1762T/G1764A mutations and patient age significantly increased the risk of disease progression to HCC.
Accumulating evidence indicates that the presence of genotype C indeed correlates with a higher prevalence of HBeAg, higher HBV DNA levels, advanced liver disease, and higher risk of developing HCC in Asian men.
2-2. Responses of HBV genotypes to antiviral therapy Many studies have demonstrated a correlation between HBV genotypes and HBV transmission, a different clinical spectrum, and the prognosis of the disease. This correlation also involves antiviral efficacy. Two major types of antiviral drugs are being used for the treatment of chronic HBV infection: drugs that directly interfere with virus replication and drugs that modulate the HBV-specific immune response. Nucleoside and nucleotide analogues impair viral replication. IFN has marked immunomodulatory but less pronounced direct antiviral effects. At present, approved treatment for chronic HBV in most countries consists of IFN-a, lamivudine, adefovir, pegylated IFN-a-2a (pegIFN-a2a), and entecavir, of which the last two have recently been approved (44, 45) .
2-2-1. IFN-a IFN-a was approved for the treatment of chronic hepatitis B in most countries in the early 1990s. IFNs are naturally occurring cytokines with immunomodulatory, anti-proliferative, and antiviral properties (46) . However, in clinical application, the effecacy rate of IFN-a is only 15z-41z (47) . This may be related to infection with different HBV genotype mutants, emergence of antibodies against IFN-a, or variations in the HBV gene induced by antiviral treatment with IFN-a (48). Ma et al. (49) compared the response to IFN therapy among Chinese patients with genotypes B, C, D, and mixed genotypes. They found that the response to IFN-a in patients with genotype B was better than in those with genotypes C and D. The response to IFN-a therapy in the mixed genotype group was less pronounced. They also demonstrated that the prevalence of HBV variations was higher in patients initially infected with a mixed genotype than in those with a single genotype. The rate of HBeAg/anti-HBe seroconversion induced by IFN-a therapy was relatively high in patients with genotype B, while only few patients with genotype C demonstrated HBeAg seroconversion. Moreover, gene variation that appeared at the precore and basic core promoter region was more likely in patients with genotype C than in those with genotype B. It has been suggested that genotype C can escape from the pressure by its high replication and variation ability, and thus, can maintain persistent viremia (33) .
The addition of a polyethylene glycol (PEG) molecule to IFN significantly prolongs the half-life of IFN and results in more sustained IFN activity. Two pegylated IFNs have been studied for the treatment of HBV, a large branched 40-kDa PEG linked to IFN-a-2a (pegIFN-a-2a) and a small linear 12-kDa PEG linked to IFN-2a (pegIFN-a-2b) (50) . Cooksly et al. (51) showed that the response rate when using pegIFN-a-2a or conventional IFN-a was higher in patients with genotype B versus C (33z versus 21z; 25z versus 6z, respectively). HBV genotypes appear to be useful to predict the response to PEG IFN, with a higher probability of HBeAg loss and HBsAg loss in patients with genotypes A (47z and 14z) and B (44z and 9z) compared with genotypes C (28z and 3z) and D (25z and 2z) (52, 53) .
IFN can cause several side effects, including influenza-like symptoms, fatigue, headache, myalgia, gastrointestinal symptoms (nausea, anorexia, and weight loss), alopecia, and local reaction at the injection site. More serious adverse events such as myelosuppression, neuropsychiatric symptoms (irritability, depression, and insomnia), neurological symptoms, and thyroid dysfunction may require dose reduction or discontinuation of the treatment (54) . Adverse events observed during treatment with PEG IFN are similar to those observed with IFN-a.
2-2-2. Nucleoside and nucleotide analogues Lamivudine, the first nucleoside analogue approved for the treatment of chronic HBV, inhibits a reverse transcriptase by competing for incorporation in the growing chain termination step and is well known for its safety and efficacy in the treatment of HBV infections, including HBV cirrhosis, regardless of the genotype (55, 56) .
Long-term lamivudine treatment for chronic HBV infection induces the emergence of lamivudine-resistant HBV YMDD mutant strains. In the case of YMDD variants, the methionine (M) is substituted with either isoleucine (I), designated as YIDD, or valine (V), called YVDD (57) , which can emerge in 15z of patients in 1 year and in 50z in 3 years after the initiation of therapy (58) and could be followed by hepatic failure, i.e., breakthrough hepatitis (59) . In the Hong Kong study, there was no difference in the antiviral response and rate of developing YMDD mutations in 82 patients with chronic hepatitis B with genotypes B and C after 1 year of lamivudine treatment (60) . In Guiyang, there is a report on 87 patients receiving lamivudine, and even The available data could only be reliably between genotypes A and D. AHB, acute hepatitis B; FHB, fulminant hepatitis B; CHB, chronic hepatitis B. The available data could only be reliably between genotypes B and C. Abbreviations are in Table 2 .
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though genotype B was dominant in this region, there was a higher mutation rate of drug resistance among patients with genotype C (61). In a Japanese study, although the emergence of the YMDD mutant was not different among infected patients with genotype A, B, or C, severe acute exacerbation of hepatitis occurred in 4 (2z) of the 185 patients with genotype C along with the emergence of YMDD mutants (62) . The emergence of lamivudine-resistant mutants is usually associated with an increase in serum HBV DNA and ALT levels, and the presence of YMDD variants has been associated with a worsening of liver histology (63) . The aim of antiviral treatment is to control HBV replication by keeping a durable suppression of serum HBV DNA to the lowest level possible and to cure liver disease by avoiding the progression of chronic hepatitis to cirrhosis and end-stage complications (64) . IFN treatment leads to a more durable response but is associated with unpleasant side effects. Lamivudine is cheaper, better tolerated, and has been shown to be effective in patients with both HBeAg-positive and -negative chronic hepatitis B. In addition, prolonged lamivudine treatment is commonly associated with the emergence of drug-resistant YMDD HBV mutants accompanied by the development of break-through hepatitis (59, 65) . Recently, other antiviral agents, e.g., adefovir, entecavir, and tenofovir have revealed usefulness in suppressing the serum HBV DNA levels. However, their long-term efficacies have not been established yet. In particular, the usage of entecavir for lamivudine-resistant mutants has shown similar mechanisms with regard to the development of resistant mutations (66) . PegIFN-a-2a has been shown to be superior to conventional IFN-a and lamivudine in the treatment of both HBeAg-positive and -negative chronic hepatitis B patients (67) .
At present, none of the above drugs are effective in achieving a sustained response in patients with HBeAgnegative chronic hepatitis B, especially in patients with genotypes C and D (68) . This is of particular importance since it has previously been demonstrated that patients with mutants show a poor long-term response to IFN-g and higher rate of viral persistence (69) . This is, because IFN-g, which is produced by Th 1 cells, inhibits Th 2 proliferation, and interleukin (IL)-4, IL-10, and IL-25, which is produced by Th 2 cells, inhibits synthesis of Th 1 cytokines and blocks the development of Th 1 cells. In this event, a novel immunomodulatory treatment approach for patients with chronic HBV infection could be to shift the balance of HBeAg-specific T cells from Th 2 to Th 1 predominance in HBeAg-positive hepatitis B patients (immune clearance phase) or to shift the balance of HBcAg-specific T cells from Th 1 to Th 2 predominance in HBeAg-negative hepatitis B patients (Tables 2 and 3) (70, 71) . A combination therapy may prove to be more effective than monotherapy in suppressing viral replication and may decrease or delay the incidence of drug resistance.
